Dirk Sibbing/LinkedIn
Nov 17, 2025, 05:31
Dirk Sibbing: New Data Strengthen the Case for Prasugrel in ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Following ISAR-REACT 5 and the recently published large Danisch registry in > 10,000 pts more data is accumulating that benefits praugrel over ticagrelor for PCI in ACS patients.
See the interesting coverage and analysis with comments from Sripal Bangalore and Ajay Kirtane on TCTMD on TUXEDO-2, a randomized comparison that focused on diabetic patients with multivessel disease undergoing PCI.”
Find more information here.
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Oct 3, 2026, 17:26Karel Kostev։ When First Anticoagulant Prescriptions Are Not Dispensed
-
Oct 3, 2026, 17:11Nabila Hasan: Thalassemia Awareness And Prevention
-
Oct 3, 2026, 17:03Pasinee Sangsiwarit: Neutrophil Dysfunction In β-Thalassemia
-
Oct 3, 2026, 16:18Mira Kassouf: Reactivating An Embryonic Gene To Treat α-Thalassemia
-
Oct 3, 2026, 15:49Behnood Bikdeli: COATED_AIR Trial Design Published as Enrollment Reaches 3,000 Patients
-
Oct 3, 2026, 15:25Vanrose Panashe Nyamangodo: A Multi-Task Deep Learning Model For Malaria And Anemia
-
Oct 3, 2026, 14:52Benny Sorensen: Glanzmann’s Thrombasthenia Finally Assigned Dedicated ICD-10 Code
-
Oct 3, 2026, 14:52The Real-World Burden Of DVT In Traumatic Fractures – ISTH
-
Oct 3, 2026, 14:41How Much Do We Really Know About The Global Burden Of Venous Thromboembolism? – World Thrombosis Day